Health go-to-market runs on trust, not hype. We build GTM strategies that turn clinical validation and outcomes data into paying customers, inside the regulatory lines that actually apply to your category.
The Problem
Clinical validation does not sell itself, and most health teams never build the bridge to adoption
Health and wellness teams put years into product development and clinical validation, then treat go-to-market as an afterthought. Meanwhile a competitor with weaker data but a sharper positioning story wins the shelf space, the payer conversation, or the app-store ranking. Trust in health categories is earned slowly through consistent, credible messaging, not a single launch push. Without a plan to translate evidence into a customer-facing story, validated products sit unsold while inferior ones get funded.
FDA and advertising rules constrain what you can say and when, and most GTM plans ignore that until it is too late
Health GTM has to run alongside clinical timelines, FDA clearance or exemption status, and substantiation requirements for health claims. A go-to-market plan that gets built before anyone checks what claims are actually defensible ends up rewritten mid-launch, or worse, flagged after spend is already committed. The fix is not avoiding bold claims, it is knowing exactly which claims your current evidence supports and building the launch narrative around those.
Health buyers, whether patients, providers, or benefits teams, evaluate for months before they move, and momentum-based launches burn out waiting for them
A consumer software launch can lean on a 30-day spike and a viral loop. A health buyer, especially a clinician or an HR benefits lead vetting a wellness vendor, is checking references, reading outcomes data, and looping in a second and third stakeholder before signing anything. Plans built around launch-week metrics read the slow early months as failure and pull budget right before the buyer was actually ready to convert.
How We Help
We start by mapping your actual regulatory position: FDA pathway or exemption status, current medical advertising constraints, and which claims your evidence base can defend today versus after further data collection. That map becomes the boundary the entire GTM plan is built inside, not a compliance checklist bolted on after positioning is done. From there we build the buyer education sequence your specific health category needs.
A DTC wellness app, a B2B2C benefits platform, and a clinician-facing device each require a different evaluation path, and we build the content, proof points, and sales sequence to match the one your buyer actually walks. Positioning comes next: translating your clinical or outcomes data into language a non-clinical buyer can act on, without softening it into a vague wellness claim that a compliance review would flag. This is the hardest part of health GTM and the part most agencies skip, because it requires someone who can read the data and write the sentence at the same time.
On execution, we work inside your existing clinical, regulatory, and marketing functions rather than handing you a deck and leaving. We coordinate directly with whoever owns compliance sign-off so claims get cleared before they go live, not after a campaign is already running. That is the difference between a growth strategy built for a normal SaaS launch and one built for a category where a single unsubstantiated claim can trigger a warning letter.
What we deliver
- Regulatory pathway map – your FDA status, advertising constraints, and defensible claims laid out before any messaging gets written
- Buyer education sequence – built for the specific evaluation path your patient, provider, or benefits buyer actually follows
- Evidence-to-positioning translation – clinical and outcomes data converted into customer-facing claims that survive compliance review
- Compliance-coordinated launch plan – messaging cleared with whoever owns regulatory sign-off before it goes live, not after
- Category authority plan – the specific content and proof points that build credibility with health buyers over a multi-month sales cycle
Health GTM fails for a specific reason: teams build the launch plan before they know which claims their evidence can actually defend. Map the regulatory ceiling first, then build the story underneath it.
Our Methodology
The engagement runs as a 90-day cycle. Weeks 1-2 are regulatory and buyer research: your current FDA or claims status, and direct research into how your specific buyer type (patient, provider, or benefits team) actually evaluates a vendor in your category. Weeks 3-6 build the positioning and buyer education sequence, with every claim checked against what your evidence base can defend, and compliance coordination built in rather than added later. Weeks 7-12 move into execution and the systems that carry education forward past launch, since health buyers rarely convert inside a single sales cycle. Where this differs from a standard GTM engagement: we treat the regulatory map as the starting constraint, not a final review step, and we optimize the first 90 days for credibility signals, not lead volume.
How We Work
The first 30 days are regulatory and buyer research, producing your claims map and a concrete picture of how your buyer evaluates and who else needs to sign off before they will move. Weeks 5-8 build the positioning, messaging, and buyer education sequence, with compliance review built into the process instead of bolted on at the end. Weeks 9-12 move into launch execution and the authority-building content and sales enablement that keep buyer education running after the initial push. You get a GTM strategist who has worked health and wellness categories and can read regulatory constraints without needing a lawyer to translate. You provide clinical data, current regulatory status, and access to whoever owns compliance sign-off. We run the market research, build the positioning, and coordinate the compliance check on every claim before it ships. Reviews happen monthly and track claims defensibility, buyer engagement by stage, and progress against the education sequence, not just top-line lead counts. Engagements typically run 6-12 months, matched to how long your category's buyers actually take to move, not to a standard agency retainer length.
- Compliant market entry
- Healthcare and wellness customer acquisition
- Category credibility with clinical or benefits buyers
- Buyer education systems that outlast the initial launch
If your health & wellness company needs go-to-market leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does go-to-market strategy cost for a health or wellness company?
Most engagements run $25K-$50K for the full regulatory mapping, positioning, and buyer education build. Where you land in that range depends on how much regulatory ambiguity exists in your claims and how many distinct buyer types you're selling to. Health GTM is a slower-return investment than a standard software launch, since the payoff shows up in months 6-12 as credibility compounds, not in the first 30 days.
How long before we see results from health go-to-market strategy?
Claims clarity and a defensible positioning story are usually locked down inside 60-90 days. Buyer engagement, meaning real conversations with providers, benefits teams, or qualified patients, typically picks up in months 3-4. Sustained pipeline and acquisition volume tend to show up in months 6-12, once the education sequence has had time to move buyers through their actual evaluation timeline.
How does your team work with our clinical and regulatory people?
Our strategist works directly with whoever owns regulatory sign-off in your organization, checking every claim before it ships rather than after a campaign is live. We pull clinical context straight from your team instead of guessing at what the data supports. This keeps launch timing realistic and prevents the rework that happens when marketing writes a claim compliance later kills.
What makes Winston Francois different from a standard GTM agency here?
Most GTM agencies default to launch-velocity tactics that assume a fast-moving consumer buyer, which does not exist in health and wellness. We build the regulatory map first and design the launch inside it, which means the plan does not need to be rewritten three weeks in. We also stay embedded through execution instead of handing off a strategy deck and leaving.
How do you measure ROI on a health go-to-market engagement?
We track claims defensibility, buyer engagement by evaluation stage, and progression through the education sequence alongside standard acquisition metrics. Early-stage success looks like qualified conversations and stakeholder buy-in, not raw lead volume. By month 6 we're tracking actual customer acquisition and how much of the education work is compounding versus needing to be repeated for every new buyer.
What kind of health or wellness company is the right fit for this?
Companies with real clinical or outcomes data who are struggling to convert that validation into customer acquisition. That covers medical device makers, health tech platforms, wellness apps with a B2B2C benefits motion, and telehealth services. The starting point is always a regulatory and claims assessment, since that determines what the rest of the strategy is allowed to say.
